Please login to the form below

Not currently logged in
Email:
Password:

WHO cheap drug talks inconclusive

Discussions between public health officials and the drug industry regarding a deal to ensure that people in poor countries can receive medicines at affordable prices end without resolution

Discussions between public health officials and the drug industry regarding a deal to ensure that people in poor countries can receive medicines at affordable prices has ended without resolution.

The meeting, which was sponsored by the United Nations' World Health Organisation (WHO), was suspended after delegates used up the six allotted days for negotiations and agreed to meet again in late April 2008 and conclude a deal later in May .

The goal of the talks is to produce guidelines which would foster research and development of affordable drugs to treat diseases prevalent in poor countries, while respecting intellectual property rights of pharmaceutical companies.

Big Pharma argues it needs strong revenues from drug sales to finance research and development into new treatments, including for diseases prevalent in developing countries. The pharmaceutical industry has also condemned the WHO draft plan, while richer countries anxious to keep the taxes of the global drug industry are also unimpressed by the plan.

Health advocates, including aid agency Medecins Sans Frontieres (MSF), say that development of drugs for poor countries is lacking. MSF said the talks, which were hosted by the Intergovernmental Working Group for Public Health, Innovation and Intellectual Property (IGWG), did see some encouraging progress, however.

A spokesperson for MSF added: "Countries are pushing WHO to be more active in resolving the access to medicines crisis, and take a pro-health approach to intellectual property. Governments are taking steps to address the fundamental reasons why investment into innovation for diseases of the poor is lacking."

The pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), said it was disappointed by the lack of a deal and called for more public funds to encourage drug development.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics